Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.91 - $7.32 $261 - $1,002
-137 Reduced 1.17%
11,526 $33,000
Q4 2023

Feb 13, 2024

BUY
$4.84 - $8.44 $1,030 - $1,797
213 Added 1.86%
11,663 $85,000
Q3 2023

Nov 30, 2023

BUY
$7.21 - $10.68 $82,554 - $122,286
11,450 New
11,450 $87.9 Million

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $55.4M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.